Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
Conditions
Keywords
Liver metastases from colorectal cancer (mCRC), Unresectable Hepatocellular carcinoma (HCC), SIR-Spheres microspheres, Y-90 resin microspheres, SIRT
Brief summary
This registry seeks to prospectively gather a large repository of comprehensive observational data reflecting routine use of SIR-Spheres in patients diagnosed with unresectable HCC or unresectable liver metastases from mCRC refractory to or intolerant to chemotherapy, in order to assess clinical response in a real-world setting and further validate the safe and appropriate use of SIR-Spheres
Detailed description
This is a global, multi-center, prospective, observational cohort study (registry) to assess real-world outcomes in patients with unresectable HCC or unresectable liver metastases from mCRC refractory to or intolerant to chemotherapy who have been prescribed SIRT with SIR-Spheres per medical decision. The study will be conducted through the involvement of approximately 845 patients from up to 44 sites in an estimated 10 countries.
Interventions
DEVICESIRT
Selective internal radiation therapy with SIR-Spheres Y90 resin microspheres.
Sponsors
Sirtex Medical
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 years or older * Confirmed diagnosis of: * Unresectable hepatocellular carcinoma (HCC) Or * Unresectable liver metastases from colorectal cancer (mCRC) refractory to or intolerant to chemotherapy * Identified as a candidate for SIR-Spheres treatment as deemed appropriate during the normal course of practice * Planned to receive SIR-Spheres treatment to the liver for the first time * Provision of signed patient informed consent
Exclusion criteria
* Prior radiation treatment to the liver Caveat: Sequential selective internal radiation therapy (SIRT) treatment is allowed * Patients participating in any interventional clinical trial with an investigational product, device, or procedure * Need for surrogate consent. Patients who are not able to consent on behalf of themselves are not eligible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change scores from baseline to follow-up timepoints of the European Organization for Research and Treatment of Cancer Quality of Life Hepatocellular Carcinoma module (EORTC QLQ-HCC18) | 24months from LPI | The EORTC QLQ-HCC18 instrument consists of 6 symptom scales and 2 single items: that measures fatigue, body image, jaundice, nutrition, pain, fever, sexual interest and abdominal swelling. Scores are based on a 4-point Likert scale (with 1 = 'not at all' to 4 = 'very much'). |
| Duration of response (DoR) | 24months from LPI | — |
| Change scores from baseline to follow-up timepoints of the EQ-5D-5L | 24months from LPI | The (EurolQol) EQ-5D-5L is comprised of five questions on mobility, self-care, pain, usual activities, and psychological status with 5 level answers, 5 being extreme and 1 minimum. |
| Change scores from baseline to follow-up timepoints of the European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) | 24months from LPI | The 30 EORTC QLQ-C30 items constitute consist of 9 domains: physical function, role function, cognitive function, emotional function, social function, fatigue, pain, nausea and vomiting, and global health status. Items are answered on a scale of 1 to 4 or 1 to 7. |
| Progression-free survival (PFS) | 24months from LPI | — |
| Liver PFS (LPFS) | 24months from LPI | — |
| Overall survival (OS) | 24months from LPI | — |
| Objective response rate (ORR) and liver response rate (LRR) | 24months from LPI | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Subsequent hepatic procedures summarized at follow-up timepoints | 24months from LPI | Subsequent hepatic procedures like number and type of retreatment and surgery are summarized at follow-up timepoints |
| Healthcare Resource Utilization summarized at follow-up timepoints | 24months from LPI | The total HCRU of each time point specified in the protocol will be summarized using descriptive statistics. |
| SAEs/SADE's rates | 24months from LPI | Serious adverse events (SAEs)/serious adverse device effects (SADEs) rates |
Countries
France, Spain, United Kingdom
Contacts
Primary ContactJanet Bell
Outcome results
None listed